ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1051

Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers

Kristin D'Silva1, Iazsmin Bauer Ventura2, Marcy Bolster3, Flavia Castelino4, Amita Sharma1, Brent Little1, Ayodeji Adegunsoye2, Mary Strek2, Sydney Montesi1 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2University of Chicago, Chicago, IL, 3Massachusetts General Hospital, Concord, MA, 4Massachusetts General Hospital/Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

Meeting: ACR Convergence 2020

Keywords: interstitial lung disease, Miscellaneous Rheumatic and Inflammatory Diseases, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Many patients with interstitial lung disease (ILD) have autoimmune features without a distinct rheumatic disease and are thus designated as having interstitial pneumonia with autoimmune features (IPAF). Rituximab (RTX) may be effective in IPAF, but relevant data are scarce. We describe 50 patients with IPAF treated with RTX at 2 large academic medical centers.

Methods: Patients age ≥18 years meeting the 2015 IPAF classification criteria and treated with rituximab were identified at two large academic medical centers, Mass General Brigham (MGB) and University of Chicago Medicine (UCM). At MGB, patients were identified using an institution-wide data repository of patients seen from 2000-2018. At UCM, patients were identified from an ILD registry between 2006-2019. Patients were excluded if they received RTX for a classifiable autoimmune disease or malignancy or if they had < 1 year of follow-up available. Clinical improvement was defined as meeting all 4 clinical domains at 1 year after RTX initiation: improvement in clinician assessment, decreased oxygen requirement, no hospitalization, and survival. Only those subjects with PFTs within 3 months prior to or 1 month after RTX initiation and 6-18 months after RTX initiation were included in the PFT analysis. PFT improvement was defined as ≥10% increase in forced vital capacity (FVC).

Results: At MGB, 36 IPAF patients (mean age 61 years, 44% female) were treated with RTX, with an average of 2.4 ± 1.3 cycles of RTX and 1.7 ± 0.6 doses per cycle (Table 1). At one year, 18 (50%) were clinically improved, 12 (33%) were stable, and 6 (17%) died from progressive respiratory failure (Table 2). Of 32 patients with PFTs available, the mean absolute change in FVC (% predicted) was +9.3% ± 16.4%. At UCM, 14 IPAF patients (mean age 53 years, 71% female) were treated with RTX with an average of 2.9 ± 2.1 cycles and 2.0 ± 0 doses per cycle. Compared to the MGB cohort, the UCM cohort was younger and had more females, Black/African American and Latinx patients, and baseline comorbidities. At the time of IPAF diagnosis, fewer patients at UCM required hospitalization for hypoxemia than at MGB (1 [7%] vs. 10 [28%]). In the UCM cohort at one year, 8 (57%) were improved, 2 (14%) were stable, and 3 (21%) died from progressive respiratory failure. Of 12 patients with PFTs available, the mean absolute change in FVC (% predicted) was +1.3% ± 6.3%. By one year, 14 (39%) patients in the MGB cohort and 7 (50%) in the UCM cohort had tapered off glucocorticoids completely. Overall at both sites, 9 patients had infections and 2 had minor infusion reactions; only 2 discontinued therapy due to adverse events (infections) during 1 year of therapy.

Conclusion: In 50 patients with IPAF treated with RTX at 2 large academic medical centers, most patients demonstrated improvement or stability at 1 year. These findings call for prospective studies, including randomized controlled trials, to further determine the risks, benefits, optimal timing, and cost effectiveness of RTX use in IPAF.


Disclosure: K. D'Silva, None; I. Bauer Ventura, None; M. Bolster, Cumberland, 9, Corbus, 9, Gilead, 5, Johnson & Johnson, 1, Abbvie, 2, Pfizer, 2; F. Castelino, Boehringer Ingelheim, 5, 8; A. Sharma, Hummingbird Diagnostics, 9, Thoracic Imaging: The Requisites, 9; B. Little, Elsevier, 9; A. Adegunsoye, Genentech, 5, Boehringer-Ingelheim, 5; M. Strek, Boehringer-Ingelheim, 2, 9, Galapagos, 9, Novartis, 9; S. Montesi, United Therapeutics, 9, Merck, 2, Wolters Kluwer, 7; H. Choi, AstraZeneca, 2, Takeda, 5, Selecta, 5, GlaxoSmithKline, 5, Horizon, 5.

To cite this abstract in AMA style:

D'Silva K, Bauer Ventura I, Bolster M, Castelino F, Sharma A, Little B, Adegunsoye A, Strek M, Montesi S, Choi H. Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/rituximab-for-interstitial-pneumonia-with-autoimmune-features-at-two-academic-medical-centers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-for-interstitial-pneumonia-with-autoimmune-features-at-two-academic-medical-centers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology